UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes

Cancer management and research, 2023-01, Vol.15, p.873-891

2023

Volltextzugriff (PDF)

EE360 Health Care Resource Utilization With Asciminib and Bosutinib Among Adults With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors: Week 48 and Week 96 Results From ASCEMBL Trial

Value in health, 2022-12, Vol.25 (12), p.S125-S126

2022

Volltextzugriff (PDF)

MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors

Value in health, 2022-07, Vol.25 (7), p.S521

2022

Volltextzugriff (PDF)

STI571: A Paradigm of New Agents for Cancer Therapeutics

Journal of clinical oncology, 2002-01, Vol.20 (1), p.325-334

Mauro, M. J.

2002

Volltextzugriff (PDF)

STI571: Targeting BCR‐ABL as Therapy for CML

The oncologist (Dayton, Ohio), 2001-06, Vol.6 (3), p.233-238

2001

Volltextzugriff (PDF)

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML

Blood, 2006-06, Vol.107 (11), p.4250-4256

2006

Volltextzugriff (PDF)

Chronic myeloid leukemia in 2006: a perspective

Haematologica (Roma), 2006-02, Vol.91 (2), p.152-152

2006

Volltextzugriff (PDF)

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

Blood, 2004-01, Vol.103 (2), p.451-455

2004

Volltextzugriff (PDF)

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

Leukemia research, 2004-05, Vol.28, p.71-73

2004

Volltextzugriff (PDF)

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

Blood, 2002-09, Vol.100 (5), p.1628-1633

2002

Volltextzugriff (PDF)

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Cancer control, 2009-04, Vol.16 (2), p.108-121

Mauro, Michael J

2009

Volltextzugriff (PDF)

Hematopathologic and cytogenetic findings in imatinib mesylate–treated chronic myelogenous leukemia patients: 14 months' experience

Blood, 2002-07, Vol.100 (2), p.435-441

2002

Volltextzugriff (PDF)

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate

Leukemia, 2003-03, Vol.17 (3), p.481-487

2003

Volltextzugriff (PDF)

Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment

Mayo Clinic proceedings, 2005-03, Vol.80 (3), p.390-402

2005

Volltextzugriff (PDF)

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Blood, 2012-11, Vol.120 (21), p.799-799

2012

Volltextzugriff (PDF)

Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used?

Mayo Clinic proceedings, 2006-03, Vol.81 (3), p.404-416

2006

Volltextzugriff (PDF)

Chronic myelogenous leukemia

Current opinion in oncology, 2001-01, Vol.13 (1), p.3-7

2001

Volltextzugriff (PDF)

HES and SMCD-eos: birds of a FIP1L1-PDGFRA feather

Blood, 2003-11, Vol.102 (9), p.3082-3082

Mauro, Michael J.

2003

Volltextzugriff (PDF)

RECENT ADVANCEMENTS IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA

Annual review of medicine, 2002-01, Vol.53 (1), p.369-381

2002

Volltextzugriff (PDF)

Hyperleukocytosis in Acute Myeloid Leukemia

The New England journal of medicine, 2003-08, Vol.349 (8), p.767-767

Mauro, Michael J

2003

Volltextzugriff (PDF)

STI571 as a Targeted Therapy for CML

Cancer investigation, 2003-01, Vol.21 (3), p.429-438

2003

Volltextzugriff (PDF)

Transplantation for chronic myelogenous leukemia: yes, no, maybe so...an Oregon perspective

Bone marrow transplantation (Basingstoke), 2003-09, Vol.32 (5), p.459-469

2003

Volltextzugriff (PDF)

Ph-positive and -negative myeloproliferative syndromes may co-exist

Leukemia, 2004-07, Vol.18 (7), p.1305-1307

2004

Volltextzugriff (PDF)

Transplantation for chronic myelogenous leukemia: yes, no, maybe so... an Oregon perspective

Bone marrow transplantation (Basingstoke), 2003-09, Vol.32 (5), p.459-469

2003

Volltextzugriff (PDF)

ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia : validating the promise of molecularly targeted therapy

Cancer chemotherapy and pharmacology, 2001-08, Vol.48, p.S77-S78

2001

Volltextzugriff (PDF)

1 – 25 von 218

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(201)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(192)
Life Sciences & Biomedicine
(145)
Humans
(105)
Biological And Medical Sciences
(70)
Female
(58)
Male
(54)
Animals
(50)
Medical Sciences
(50)
Middle Aged
(36)
Adult
(35)
Aged
(30)
Technology
(30)
Physical Sciences
(29)
Medicin Och Hälsovetenskap
(25)
Engineering
(23)
Fundamental And Applied Biological Sciences. Psychology
(21)
Cardiovascular System & Cardiology
(19)
Oncology
(19)
Hematology
(18)
Imatinib Mesylate
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes

EE360 Health Care Resource Utilization With Asciminib and Bosutinib Among Adults With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors: Week 48 and Week 96 Results From ASCEMBL Trial

MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors

STI571: A Paradigm of New Agents for Cancer Therapeutics

STI571: Targeting BCR‐ABL as Therapy for CML

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML

Chronic myeloid leukemia in 2006: a perspective

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Hematopathologic and cytogenetic findings in imatinib mesylate–treated chronic myelogenous leukemia patients: 14 months' experience

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate

Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used?

Chronic myelogenous leukemia

HES and SMCD-eos: birds of a FIP1L1-PDGFRA feather

RECENT ADVANCEMENTS IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA

Hyperleukocytosis in Acute Myeloid Leukemia

STI571 as a Targeted Therapy for CML

Transplantation for chronic myelogenous leukemia: yes, no, maybe so...an Oregon perspective

Ph-positive and -negative myeloproliferative syndromes may co-exist

Transplantation for chronic myelogenous leukemia: yes, no, maybe so... an Oregon perspective

ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia : validating the promise of molecularly targeted therapy

Suchergebnisse filtern